23.13 USD
↘ 0.37 (1.57%)AT CLOSE (11:59 AM EDT)
Zymeworks Inc.
ZYMENASDAQ • USD
23.14
↗ 0.01 (0.04%)
POST MARKET (AS OF 07:27 PM EDT)
Post Market
AS OF 07:27 PM EDT
23.14
↗ 0.01 (0.04%)
Market: CLOSED
ZYME is currently priced at $23.18. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bearish long-term moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Aug 6, 2026.
Open?$23.50
High?$23.84
Low?$23.10
Prev. Close?$23.50
Volume?673.7K
Avg. Volume?513.9K
VWAP?$23.29
Rel. Volume?1.31x
Bid / Ask
Bid?$22.87 × 300
Ask?$25.00 × 100
Spread?$2.13
Midpoint?$23.94
Valuation & Ratios
Market Cap?1.7B
Shares Out?73.0M
Float?46.0M
Float %?62.3%
P/E Ratio?N/A
P/B Ratio?10.57
EPS?-$1.40
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Themes
Employees
264
Market Cap
1.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2017-04-28
Address
108 PATRIOT DRIVE, SUITE A
MIDDLETOWN, DE 19709
Phone: 302-274-8744
MIDDLETOWN, DE 19709
Phone: 302-274-8744
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?5
Momentum?3
Short Sent.?39
Piotroski F-Score?2/9Weak
Altman Z-Score?0.41Distress
Confidence?68%Moderate
Short InterestHigh
Short % of Float?8.93%Elevated
Short Interest?4.1M
Days to Cover?7.6
Free Float46.0M
Avg Daily Volume542.3K
Settlement Date2026-07-15
Financial Health
Current Ratio?10.82Strong
Quick Ratio?10.82Strong
Cash Ratio?6.85Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score50/100
P/E?N/A▾
P/B?10.57HIGH▾
Peers100
S&P18
P/S?21.28HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-13.8CHEAP▾
S&P97
EV/Sales?18.27HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-62.7%WEAK▾
S&P3
ROA?-21.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-77037000
Enterprise Value?$1.5B
Fundamentals ratios updated end of day